MedToolboxClinician’s desktop Search tools: egfr, depression, due date…/ Tool guides Sign in

GLP-1 Weight Loss Tracker: Wegovy, Mounjaro and Saxenda

Check weight loss on a GLP-1 medicine against the NICE continuation rules.

By Dr Amer Sheikh, GP Updated 17 October 2026 Clinical review pending

Runs in your browser. Nothing you enter is stored or sent anywhere.

NICE continuation rules

MedicineRule
Semaglutide (Wegovy)Stop if under 5% weight loss after 6 months (NICE TA875)
Tirzepatide (Mounjaro)Stop if under 5% weight loss after 6 months on the highest tolerated dose (NICE TA1026)
Liraglutide (Saxenda)Stop if under 5% weight loss after 12 weeks on 3 mg daily (NICE TA664)

Private prescribing follows the product licence, which uses similar rules. Review adherence, side effects and dose at each check.

Frequently asked questions

How much weight should I lose on Wegovy?

NICE expects at least 5% of starting weight by 6 months to continue.

What is the NICE rule for Mounjaro?

Stop if less than 5% weight loss after 6 months on the highest tolerated dose.

How is percentage weight loss calculated?

(Starting weight − current weight) ÷ starting weight × 100.

Every tool you use, on one free desk

GLP-1 weight tracker is one of more than 150 UK primary care tools on MedToolbox. Pin your favourites and sync them to every device. Free for healthcare professionals, always.

Open MedToolbox

Related tools

BMI and waist-to-heightWith NICE ethnicity thresholdsAUDIT-CAlcohol use screenLipid target trackerNon-HDL reduction on statinsOpen on your deskGLP-1 weight tracker on your desk

References

  1. NICE TA875: Semaglutide for managing overweight and obesity. nice.org.uk
  2. NICE TA1026: Tirzepatide for managing overweight and obesity. nice.org.uk
  3. NICE TA664: Liraglutide for managing overweight and obesity.

MedToolbox supports, and does not replace, clinical judgement, national guidance and local policy.